Gene: BRAF ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913351
rs121913351
BRAF
0.800 GeneticVariation UNIPROT

dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE <b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. 31416288

2019
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE <b>:</b> The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. 31416288

2019
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE <i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer. 29295876

2018
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE <i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer. 29295876

2018
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE (2018) report that chondroitin-4-sulfate, which is found in a common supplement meant to alleviate degenerative joint disorders, promotes the growth of BRAF V600E mutant melanoma. 29547718

2018
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE (2018) report that chondroitin-4-sulfate, which is found in a common supplement meant to alleviate degenerative joint disorders, promotes the growth of BRAF V600E mutant melanoma. 29547718

2018
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE 21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response. 22608338

2012
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE 21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response. 22608338

2012
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanoma cell lines expressing (WT)B-Raf and (WT)Ras grew with similar proliferation rates, showed constitutive activation of ERK1/2, and had similar levels of B-Raf expression and B-Raf kinase activity as melanoma cell lines expressing the activating V600E mutation ((V600E)B-Raf). 16452469

2006
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanoma cell lines expressing (WT)B-Raf and (WT)Ras grew with similar proliferation rates, showed constitutive activation of ERK1/2, and had similar levels of B-Raf expression and B-Raf kinase activity as melanoma cell lines expressing the activating V600E mutation ((V600E)B-Raf). 16452469

2006
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. 19561646

2009
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. 19561646

2009
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 21107323

2010
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 21107323

2010
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. 22395615

2012
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. 22395615

2012
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhanced melanoma cell death in response to cytotoxic drugs, MEK- and BRAF(V600E)-specific inhibitors, and soluble or membrane-bound TRAIL. 22553342

2012
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhanced melanoma cell death in response to cytotoxic drugs, MEK- and BRAF(V600E)-specific inhibitors, and soluble or membrane-bound TRAIL. 22553342

2012
dbSNP: rs121913227
rs121913227
BRAF
0.800 GeneticVariation BEFREE Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31). 23651150

2014
dbSNP: rs121913364
rs121913364
BRAF
0.720 GeneticVariation BEFREE Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31). 23651150

2014
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanomas that contain B-RAF(V600E) mutations respond transiently to RAF and MEK inhibitors; however, resistance to these agents remains a formidable challenge. 23737487

2013
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanomas that contain B-RAF(V600E) mutations respond transiently to RAF and MEK inhibitors; however, resistance to these agents remains a formidable challenge. 23737487

2013
dbSNP: rs113488022
rs113488022
BRAF
0.800 GeneticVariation BEFREE Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extracellular signal regulated kinase (ERK) inhibitors in vitro and in vivo. 24077403

2013
dbSNP: rs121913377
rs121913377
BRAF
0.800 GeneticVariation BEFREE Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extracellular signal regulated kinase (ERK) inhibitors in vitro and in vivo. 24077403

2013